Lannett And FDA To Meet Over Insulin Glargine Biosimilar
Follow-On To Lantus Being Developed With China’s HEC Pharm
For its proposed biosimilar to Lantus, Lannett promised in early February this year “to send the FDA our briefing book within the next few weeks and meet with them later this fiscal year to review the development plan.” The date for the meeting has now been confirmed.
